Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Abiraterone + Abivertinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Abiraterone||Zytiga||CB7630||Hormone - Anti-androgens 38||Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov).|
|Abivertinib||Avitinib|AC0010|AC0010MA||BTK inhibitor 32 EGFR Inhibitor 3rd gen 24||Abivertinib (AC0010) is a BTK inhibitor and a third-generation EGFR inhibitor that blocks the activity of mutant forms of EGFR while sparing wild-type EGFR, which potentially results in increased apoptosis and cell cycle arrest, and decreased viability and colony formation, and inhibits tumor growth (PMID: 27573423, PMID: 31310800).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05361915||Phase II||Abiraterone + Abivertinib||Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer||Not yet recruiting||USA||0|